May 25th, 2011

FDA Approves Xience Nano for Small Vessels

The FDA has approved the Xience Nano everolimus-eluting stent, Abbott has announced. The stent is based on the same platform as the popular Xience V stent, and can be used in vessels as small as 2.25 mm. The approval was based on results from the SPIRIT Small Vessel clinical trial. The rate of target lesion failure was 8.1% in that trial, similar to the rate observed in the SPIRIT trials with Xience V.

Comments are closed.